How to build a cardio‐oncology service?
- 17 October 2018
- journal article
- editorial
- Published by Wiley in European Journal of Heart Failure
- Vol. 20 (12), 1732-1734
- https://doi.org/10.1002/ejhf.1336
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Activity and outcomes of a cardio‐oncology service in the United Kingdom—a five‐year experienceEuropean Journal of Heart Failure, 2018
- Cardio-Oncology Services: rationale, organization, and implementationEuropean Heart Journal, 2018
- Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunctionEchocardiography, 2018
- Anthracycline‐induced cardiomyopathy: secrets and liesEuropean Journal of Heart Failure, 2018
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart AssociationCirculation, 2018
- SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumabMedical Oncology, 2017
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Journal of Heart Failure, 2016
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Role of Biomarkers in Chemotherapy-Induced CardiotoxicityProgress in Cardiovascular Diseases, 2010
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004